RVTY — Revvity Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $155.11
- YTD price return
- +60.32%
- YTD total return
- +60.72%
- Market cap
- 17.3B
- Enterprise value
- 19.7B
- Shares outstanding
- 111.6M
- 52W low
- $81.22
- 52W high
- $171.74
- From 52W high
- -9.68%
- From 52W low
- +90.98%
- 52W range
- 82%$81.22–$172
- Beta
- 1.07
Volume
- Rel volume
- 0.86×
- 30D volume
- 2M
- 30D $ vol
- 304.7M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$1.3M
- Insider net 1Y
- −$6.0M
Form 4 transactions by trade date, as filed; latest on file 2026-10-01.
Fundamentals
- Sales (ttm)
- 2.9B
- Sales/share
- $26.09
- EPS (ttm)
- $2.10
- FCF (ttm)
- 558.1M
- FCF/share
- $5.00
- Book value/share
- $64.78
- Net margin
- 8.16%
- ROE
- 3.29%
- ROA
- 1.97%
- Debt / equity
- 0.36×
- Current ratio
- 1.80
Growth (CAGR, ttm) · 10Y
- Sales
- +3.99%+0.87%-9.71%+3.12%
- Net income
- -16.47%-33.70%-27.45%+0.13%
- FCF
- +10.79%+53.67%-16.55%+7.20%
- Shares
- -3.81%-3.48%-0.09%+0.20%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -11.03%-31.15%-27.52%+0.01%
- Sales/share
- +8.10%+4.51%-9.63%+2.93%
- FCF/share
- +15.17%+59.21%-16.47%+6.99%
- Book value/share
- -0.48%+0.72%+11.36%+12.99%
- Dividend/share
- +0.00%-0.53%+0.00%+0.00%
- Price
- +73.33%+21.94%-1.68%+11.74%
- Total return
- +73.76%+22.26%-1.44%+12.06%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 73.8×
- P/OI (ttm)
- 48.2×
- Fwd P/E
- 25.4×
- P/S (ttm)
- 5.9×
- P/B (mrq)
- 2.4×
- P/FCF (ttm)
- 31.0×
- EV/EBITDA (fy)
- 25.5×
- EV/Sales (ttm)
- 6.8×
- FCF yield (ttm)
- 3.22%
- Dividend yield (fwd)Div yield
- 0.18%
- Dividend yield (ttm)
- 0.18%
- Dividend/share (fwd)
- $0.28
- Buyback yield (realized, 1y)
- 3.81%
- Shareholder yield (realized, 1y)
- 4.08%
- Buyback yield (cash, ttm)
- 2.75%
- Shareholder yield (cash, ttm)
- 2.93%
Vs own 10Y history
- P/E
- 92nd
- P/OI
- 95th
- P/S
- 97th
- P/B
- 40th
- P/FCF
- 63rd
Bar = where today’s multiple sits in RVTY’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR −16.3%10Y CAGR +3.6%YoY −1.6%EPS (diluted)
5Y CAGR −20.4%10Y CAGR +1.0%YoY +2.2%Free cash flow
5Y CAGR −9.3%10Y CAGR +7.0%YoY +56.7%TTM: operating cash flow $627.6M, capex −$69.5M
Q2 2026: operating cash flow $191.9M, capex −$11.1M
Shares (diluted)
5Y +4.0%10Y +2.9%YoY −5.0%Dividend per share
5Y CAGR +0.0%10Y CAGR +0.0%YoY +0.0%About Revvity#
Data provided bySource: Twelve DataRevvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.
Waltham, MA·11,000 employees·Diagnostics & Research·revvity.com·As of Oct 28, 2026
Recent filings#
- Nov 3Earnings · Earnings release — EPS $1.38 vs $1.29 est. (+7.0%) 7.8%
- Aug 4Earnings · Earnings release — EPS $1.41 vs $1.23 est. (+14.6%); revenue $729.7M (+1% y/y) 3.3%
ETFs holding RVTY#
27 of the 193 ETFs ChartRow carries live hold RVTY. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| VBR | Vanguard Small-Cap Value ETF | 0.3% |
| XLV | Health Care Select Sector SPDR Fund | 0.2% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.2% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
| SPYV | SPDR Portfolio S&P 500 Value ETF | 0.0% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
